Calvin Chao, MD, MBA is the Vice President of Medical Science at Arter.ai, where he provides clinical leadership to R&D for new AI-enabled models in breast, colorectal, and prostate cancer. He also leads medical affairs in support of physician education and medical communications for the ArteraAI MMAI platform. Calvin is a seasoned medical executive with 22 years of experience in the oncology diagnostics and biopharmaceutical industries. As Sr VP of Medical Affairs at Tempus AI, he built a medical infrastructure for external research collaborations and product commercialization for tissue NGS and ctDNA based assays across all cancer types. As VP of Medical Affairs at Genomic Health and Exact Sciences, he led global clinical research to define clinical utility for the Oncotype DX breast cancer test enabling worldwide adoption and reimbursement. Earlier in his career, Calvin practiced inpatient and outpatient internal medicine for 10 years and served as a Chief of Medicine at Kaiser Permanente. His pharmaceutical career included building medical affairs teams at Onyx, PDL Biopharma, TAP Pharmaceuticals, and SmithKline Beecham. He also served briefly as Sr Medical Director for CIGNA HealthCare in California.